生长激素以外的促生长疗法研究进展  

Progress on growth promoting therapies other than growth hormone

作　　者：薛初晴 傅君芬[1] XUE Chuqing;FU Junfen(Department of Endocrinology,Children’s Hospital,Zhejiang University School of Medicine,National Clinical Research Center for Child Health,National Regional Medical Center for Children,Hangzhou 310052,China)

机构地区：[1]浙江大学医学院附属儿童医院内分泌科国家儿童健康与疾病临床医学研究中心国家儿童区域医疗中心,浙江杭州310052

出　　处：《浙江大学学报（医学版）》2022年第4期515-520,共6页Journal of Zhejiang University(Medical Sciences)

基　　金：“十三五”国家科技支撑计划(2016YFC1305301)。

摘　　要：重组人生长激素是身材矮小症儿童的经典治疗药物。近年来随着儿童生长机制的进一步探明,生长激素以外的促生长疗法的研究取得较大进展。重组人胰岛素样生长因子1是治疗原发性胰岛素样生长因子1缺乏的主要药物。C型钠尿肽为因软骨发育不全导致身材矮小症儿童提供了治疗选择。生长激素释放肽类似物能刺激生长激素释放,用于促生长治疗。此外,促性腺激素释放激素激动剂、芳香化酶抑制剂等可延缓患儿骨龄进展,对改善终身高有一定益处。现就这些除生长激素以外的促生长疗法研究进展进行综述,以期为临床身材矮小症患儿的治疗提供更多选择。Recombinant human growth hormone is a classical therapeutic drug for children with short stature.In recent years,as the mechanism of growth in children has been further explored,growth-promoting therapies other than growth hormone have made great progress.Recombinant human insulin-like growth factor(IGF)-1 is the main treatment for primary IGF-1 deficiency,and C-type natriuretic peptide(CNP)offers a therapeutic option for children with short stature due to chondrodysplasia.Growth hormone-releasing peptide analogues stimulate growth hormone release and may be used for growth-promoting therapy.In addition,gonadotropin-releasing hormone analogue(Gn RHa)and aromatase inhibitors may delay the bone age in children and may be beneficial in improving final height.In this article,the research progress of growthpromoting therapies other than growth hormones is reviewed to provide more options for the clinical treatment of children with short stature.

关 键 词：身材矮小症 重组人胰岛素样生长因子-1 C型钠尿肽 生长激素释放肽类似物 促性腺激素释放激素激动剂 芳香化酶抑制剂 综述 

分 类 号：R588[医药卫生—内分泌] R725.8[医药卫生—内科学]